{"disease":{"id":"lymphoma-follicular","name":"lymphoma follicular"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01584141","title":"Study of Lymphoma in Asia","phase":"","overall_status":"COMPLETED","enrollment_count":13433,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03869619","title":"REal World Data in LYmphoma and Survival in Adults","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06339255","title":"Italian Observational Study on CAR-T Therapy for Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":5300,"lead_sponsor_name":"Paolo Corradini","has_results":false},{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02793583","title":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":710,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01804686","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02240316","title":"An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":688,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04224493","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":612,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT06337318","title":"Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01311232","title":"Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04858568","title":"Immune Responses to COVID-19 Vaccination in Lymphoma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":592,"lead_sponsor_name":"University Hospital Southampton NHS Foundation Trust","has_results":false},{"nct_id":"NCT04663347","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":543,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT04587388","title":"Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"European Hematology Association - Lymphoma Group","has_results":false},{"nct_id":"NCT06785818","title":"Long-term Follow up Local Registry Study of Kymriah in South Korea","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03375619","title":"Long-term Follow-up Study of Patients Receiving CAR-T Cells","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT04799275","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":422,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04952974","title":"B-cell Chronic Lymphoid Malignancies Markers","phase":"","overall_status":"UNKNOWN","enrollment_count":420,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT01897571","title":"Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT05633615","title":"Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT02631044","title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":false},{"nct_id":"NCT01077518","title":"Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":346,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01799889","title":"Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":326,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04594642","title":"A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":317,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01582776","title":"Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"The Lymphoma Academic Research Organisation","has_results":false},{"nct_id":"NCT02809053","title":"A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"Archigen Biotech Limited","has_results":true},{"nct_id":"NCT01321541","title":"Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"CTI BioPharma","has_results":true},{"nct_id":"NCT02348216","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06724237","title":"Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":294,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05848765","title":"Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT07173790","title":"Watch and Wait or Worry and Wait in Indolent Lymphoma","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":250,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06526793","title":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05458297","title":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":223,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05541341","title":"Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07519772","title":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03501576","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT06608147","title":"MOLyF : Bone Marrow and Follicular Lymphoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT01953692","title":"A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03162536","title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":190,"lead_sponsor_name":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","has_results":false},{"nct_id":"NCT01307267","title":"A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04849351","title":"Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT01000753","title":"Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04803201","title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":170,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03997968","title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Cyteir Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06022029","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoNano Medicine, Inc.","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT04859920","title":"Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region","phase":"","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT00695786","title":"Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02661035","title":"Allo HSCT Using RIC for Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}